Immunohistochemical analysis of Fas and FLIP in prostate cancers
Abstract:Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH. Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS 2009; 117: 28–33.
Fas-mediated apoptosis is considered a principal pathway for apoptosis induction in normal and cancer cells. Expression of Fas has been reported in prostate tissues several times, but the data were not consistent. Expression of FLICE-like inhibitory protein (FLIP), an inhibitor of Fas-mediated apoptosis, has not been studied by immunohistochemistry in prostate tissues. The aim of this study is to explore whether alterations of Fas and FLIP expression occur in prostate cancer tissues. We analyzed the expression of Fas and FLIP in 107 prostate adenocarcinoma tissues by immunohistochemistry using a tissue microarray approach. Normal glandular cells of the prostates strongly expressed both Fas and FLIP proteins. Prostate intraepithelial neoplasm also showed a strong Fas immunoreacitity. Fas expression was strongly positive in 60 cancers (56.1%), but the remaining 47 cancers showed no (6.5%) or markedly decreased (37.4%) Fas immunostaining compared with the normal glandular cells of the same patients. By contrast, FLIP expression was strong in most (103/107; 96.3%) of the cancers, and only four cancers (3.7%) showed decreased immunoreactivities compared with the normal cells. The decreased expression of Fas was not associated with pathologic characteristics, including FLIP expression, size of the cancers, age, Gleason score and stage. The decreased expression of Fas in a large fraction of prostate cancers compared with their normal cells suggested that loss of Fas expression might play a role in tumorigenesis in some prostate cancers possibly by inhibiting apoptosis mediated by Fas.
Document Type: Research Article
Affiliations: 1: Department of Pathology, College of Medicine, the Catholic University of Korea, Seoul; 2: Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 3: Department of Urology, College of Medicine, the Catholic University of Korea, Seoul; and 4: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Publication date: January 1, 2009